


# Management of metastatic disease<sup>1</sup>



<sup>1</sup> Recommendations from TA61, TA118, TA176 and TA212 are also relevant to this group of patients

<sup>2</sup> At the time of publication (November 2011), irinotecan did not have UK marketing authorisation for second-line combination therapy. Informed consent should be obtained and documented.